Medtech start-up Piomic closes seed round

27.04.2018 14:18

Related tags

Piomic Team

Piomic develops an innovative device for the treatment of chronic wounds. After encouraging first clinical trial results, the company was able to attract a group of business angels and private investors.

Piomic, a Zurich based MedTech start-up has successfully raised an undisclosed seed round investment with the continuing commitment of existing business angels and a pool of private investors, after receiving strong initial results from first patients enrolled in Piomic´s clinical pilot trial. Proceeds of the financing will be used to accelerate the development of its advanced wound care product, expand its team and operations and to further strengthen the clinical body of evidence supporting the effectiveness of its core technology.

Piomic develops an innovative non-invasive medical device for treatment of chronic wounds. Driven by diabetes and the effects of an over aging population, hard-to-heal wounds remain a major challenge for modern health care systems. With more than 50 million patients affected, the company wants to provide clinical and economic benefits to institutions treating non-healing wounds.

“We are pleased to have such a strong group of investors supporting our company” said Christopher Hertz, co-founder and CEO of Piomic. “The continuous positive feedback of patients and physicians is a positive endorsement of Piomic´s therapeutic approach. We believe that life shouldn't be defined by a medical condition. By developing a therapy which is safe and effective we hope to set a better future for everyone in need.”

In addition to the round, Piomic is excited to welcome Bertrand Hughes as an additional key advisor to the company. Bertrand was previously Global Business Director of the Electrical Stimulation business unit at Mölnlycke Health Care and comes with extensive experience in the advanced wound care and MedTech market.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related News

Related tags

Read more about

Principal

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.